Dextran-modified Quercetin-Cu(II)/hyaluronic acid nanomedicine with natural poly(ADP-ribose) polymerase inhibitor and dual targeting for programmed synthetic lethal therapy in triple-negative breast cancer-Reference-Cited by-同舟云学术

Dextran-modified Quercetin-Cu(II)/hyaluronic acid nanomedicine with natural poly(ADP-ribose) polymerase inhibitor and dual targeting for programmed synthetic lethal therapy in triple-negative breast cancer

Published:2021-01 Issue: Volume:329 Page:136-147
ISSN:0168-3659
Container-title:Journal of Controlled Release
language:en
Short-container-title:Journal of Controlled Release

Author:

Cheng Hung-Wei,Chiang Chih-Sheng,Ho Hsin-Yao,Chou Syun-Hong,Lai Yen-Ho,Shyu Woei-Cherng,Chen San-Yuan

Funder

Ministry of Science and Technology, Taiwan

Ministerio de Ciencia y Tecnología

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference39 articles.

1. Defining ‘chromosomal instability’;Geigl;Trends Genet.,2008

2. The multifaceted role of chromosomal instability in cancer and its microenvironment;Bakhoum;Cell,2018

3. Context is everything: aneuploidy in cancer;Ben-David;Nat. Rev. Genet.,2020

4. Synthetically lethal nanoparticles for treatment of endometrial cancer;Ebeid;Nat. Nanotechnol.,2018

5. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase;Bryant;Nature,2005

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biopolymer-Based Nanomedicine for Cancer Therapy: Opportunities and Challenges;International Journal of Nanomedicine;2024-07

2. Dual-targeted nanoparticulate drug delivery systems for enhancing triple-negative breast cancer treatment;Journal of Controlled Release;2024-07

3. Application of Nanoparticles for Efficient Delivery of Quercetin in Cancer Cells;Current Medicinal Chemistry;2024-03

4. Emerging natural polymer-based architectured nanotherapeutics for the treatment of cancer;International Journal of Biological Macromolecules;2024-03

5. Quercetin induces ferroptosis in gastric cancer cells by targeting SLC1A5 and regulating the p-Camk2/p-DRP1 and NRF2/GPX4 Axes;Free Radical Biology and Medicine;2024-03